The company has also appointed Briggs Morrison as Chair of the Board and John Crowley as an independent director.

The new leadership will steer Actithera as it moves its lead fibroblast activation protein (FAP)-targeted radioligand therapy into clinical development. The company raised a USD 75.5 million Series A in July 2025.

Steven Kelly

Steven Kelly has more than 30 years of biotech leadership experience. Most recently he was President and CEO of Carisma Therapeutics, where he took the company from an academic platform to a publicly traded, clinical-stage company and raised more than USD 300 million. He has also held senior roles at BioVex, Sanofi, IDEC Pharmaceuticals and Amgen. Founder Andreas Goutopoulos continues as President and Head of R&D, leading the company’s science and discovery pipeline.

“Our priorities are clear: advance the lead FAP-targeted program into clinical development, continue building the pipeline behind it, and establish the capabilities needed to execute with rigor and discipline,” says Steven Kelly.

Briggs Morrison

Morrison is a medical oncologist and CEO of Crossbow Therapeutics. He also chairs Arvinas and sits on the board of CRISPR Therapeutics. He previously held executive roles at Syndax Pharmaceuticals, AstraZeneca, Pfizer and Merck, where he oversaw clinical development of oncology medicines including Tagrisso, Imfinzi and Lynparza.

John Crowley

Crowley was most recently CFO of Centessa Pharmaceuticals ahead of its USD 7.8 billion acquisition by Eli Lilly. Before that, as CFO of Fusion Pharmaceuticals, he helped take the radioligand company through its Nasdaq IPO and its acquisition by AstraZeneca.